The Natural History of TRPV4 Neuropathy

NCT ID: NCT05600764

Last Updated: 2025-11-04

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 70 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-12-15
• Study Completion Date: 2048-12-31

Brief Summary

The goal of this research is to document the natural history of neuropathy in patients with a confirmed genetic mutation in the TRPV4 gene. The investigators are searching for patients willing to participate in a 6-year long study to document the symptoms of TRPV4-associated disease and their progression over time. Participation requires annual study visits at Johns Hopkins for adult and juvenile participants.

Detailed Description

Genetic variants in the transient receptor potential cation channel subfamily V member 4 (TRPV4) gene are known to cause different forms of inherited neuropathy that can manifest with muscle weakness, sensory loss, and problems with the vocal cords. These different conditions can be referred to as Charcot-Marie-Tooth disease 2C, scapuloperoneal spinal muscular atrophy, or congenital distal spinal muscular atrophy. For unclear reasons, the symptoms vary significantly among the patients, from mild to severe impact and from early childhood onset to adult onset. Research has shown that disease-causing changes in the TRPV4 gene cause overactivation of TRPV4, which could theoretically be treated with a TRPV4 blocking drug.

There have been many case reports about patients with TRPV4-associated disease, but never has there been a large cohort evaluation to study the natural history of the disease to document the frequency and severity of symptoms and how they change over time. Understanding the different sub-types of disease and how they progress over time is essential knowledge to design clinical trials to evaluate the effectiveness of potential treatments.

The investigators are therefore seeking patients with a confirmed mutation in the TRPV4-gene to participate in this research project. It requires annual study visits at Johns Hopkins (Baltimore, Maryland) for adults and pediatric participants. The study is designed to follow patients for six years and testing is scheduled to occur over two days for each visit. Participants will be reimbursed for travel expenses and hotel accommodations, and all tests will be performed free of charge.

Planned testing includes thorough neurological exams, nerve conduction studies, standardized questionnaires, brain MRIs, skeletal X-rays and bone density scans (DEXA), vocal cord and voice assessments, retinal (eye) scans, and a series of tests to evaluate the ability to perform tasks of daily living such as getting up from a chair or walking for six minutes. The investigators will also collect blood samples from each participant to be used for laboratory research.

Conditions

TRPV4 Gene Mutation

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Patient is aged 3-80 years with a documented mutation in the TRPV4 gene and a clinical phenotype consistent with TRPV4-associated disease (as determined by the investigator) OR
• The patient has a first-degree relative (parent, child, sibling, half-sibling, aunt, uncle, grandparent, or grandchild) with a documented disease-causing mutation AND a clear link between that family member and the affected patient AND a clinical phenotype consistent with TRPV4-associated disease.
• Patients with a variant of unknown significance in TRPV4 and a clinical phenotype possibly consistent with TRPV4-associated disease will be eligible for initial enrolment, but continued eligibility will be determined based on whether the observed clinical phenotype is consistent with TRPV4-associated disease (as determined by the investigator).
• Participant or legal guardian for patients under 18 years of age is capable of giving signed informed consent.

Exclusion Criteria

• Medical history of other concomitant neurological disease or clinically significant physical exam/laboratory result that, in the opinion of the investigator, would render the patient being unsuitable for the study.
• Patients with a TRPV4 variant of unknown significance who are initially enrolled but then deemed to be unlikely to have a phenotype consistent with TRPV4-associated disease will no longer be eligible and their clinical data will be deleted.

• Minimum Eligible Age: 3 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Muscular Dystrophy Association

OTHER

Sponsor Role: collaborator

Actio Biosciences, Inc.

INDUSTRY

Sponsor Role: collaborator

Johns Hopkins University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Charlotte Sumner, MD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Locations

Johns Hopkins

Baltimore, Maryland, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Betty Hu

Role: CONTACT

xhu38@jhu.edu

443-250-4699

Simone Thomas

Role: CONTACT

sthom125@jhmi.edu

(410) 614-4188

Facility Contacts

Betty Hu

Role: primary

xhu38@jhu.edu

410-502-2705

Other Identifiers

IRB00341314

Identifier Type: -

Identifier Source: org_study_id